(Q45141053)

10 December 2017

title

Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects (English)

1 reference

10 December 2017

1 reference

Aimee K Bence

1

1 reference

10 December 2017

Eric B Anderson

2

1 reference

10 December 2017

Maqbool A Halepota

3

1 reference

10 December 2017

Michael A Doukas

4

1 reference

10 December 2017

Phillip A DeSimone

5

1 reference

10 December 2017

George A Davis

6

1 reference

10 December 2017

Deborah A Smith

7

1 reference

10 December 2017

Kevin M Koch

8

1 reference

10 December 2017

Andrew G Stead

9

1 reference

10 December 2017

Steve Mangum

10

1 reference

10 December 2017

Carolyn J Bowen

11

1 reference

10 December 2017

Neil L Spector

12

1 reference

10 December 2017

Showchien Hsieh

13

1 reference

10 December 2017

Val R Adams

14

1 reference

10 December 2017

publication date

1 January 2005

1 reference

Investigational New Drugs

10 December 2017

published in

1 reference

10 December 2017

volume

23

1 reference

10 December 2017

issue

1

1 reference

10 December 2017

page(s)

39-49

1 reference

Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development.

10 December 2017

cites work

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

12 December 2020

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

12 December 2020

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

1 reference

12 December 2020

Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line

1 reference

12 December 2020

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

12 December 2020

EGFR and cancer prognosis

1 reference

12 December 2020

Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance.

1 reference

12 December 2020

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

1 reference

12 December 2020

c-erbB growth-factor-receptor proteins in ovarian tumours

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

12 December 2020

Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence

1 reference

12 December 2020

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

1 reference

12 December 2020

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

1 reference

12 December 2020

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

1 reference

12 December 2020

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.

1 reference

12 December 2020

Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.

1 reference

12 December 2020

Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth

1 reference

12 December 2020

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells

1 reference

12 December 2020

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

10.1023/B:DRUG.0000047104.45929.EA

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

1017219321

0 references

1 reference